Zealand’s Dasiglucagon Down But Not Out In CHI?
Zealand has been hit by an unexpected Phase III failure for its glucagon analog product dasiglucagon in congenital hyperinsulinism, but all may not be lost for the indication.
Zealand has been hit by an unexpected Phase III failure for its glucagon analog product dasiglucagon in congenital hyperinsulinism, but all may not be lost for the indication.